{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:38:50Z","timestamp":1762299530018,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"publisher","award":["1200020109"],"award-info":[{"award-number":["1200020109"]}],"id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Glycated albumin (GA) is a marker of short-term glycemic control and is strongly associated with the occurrence of diabetes. Previous studies have shown an association between GA and the effect of clopidogrel therapy on ischemic stroke. However, limited information is available regarding this relationship in acute coronary syndrome (ACS) patients. In this study, we evaluated the effect of GA on platelet P2Y12 inhibition by clopidogrel in patients with ACS.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Consecutive Chinese patients with ACS who received loading or maintenance doses of clopidogrel in addition to aspirin were recruited. At least 12\u00a0h after the patient had taken the clopidogrel dose, thromboelastography (TEG) and light transmittance aggregometry (LTA) were used to calculate the quantitative platelet inhibition rate to determine clopidogrel-induced antiplatelet reactivity. A prespecified cutoff of the maximum amplitude of adenosine diphosphate (ADP)-induced platelet-fibrin clot strength\u2009&gt;\u200947\u00a0mm plus an ADP-induced platelet inhibition rate\u2009&lt;\u200950% assessed by TEG or ADP-induced platelet aggregation\u2009&gt;\u200940% assessed by LTA to indicate low responsiveness to clopidogrel were applied for evaluation. Patients were categorized into two groups based on a GA level of 15.5%, the cutoff point indicating the development of early-phase diabetes. Multivariate linear regression analysis was used to assess the interaction of GA with clopidogrel antiplatelet therapy.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 1021 participants were evaluated, and 28.3% of patients (289 of 1021) had low responsiveness to clopidogrel assessed by TEG. In patients with elevated GA levels, low responsiveness to clopidogrel assessed by TEG was observed in 33.7% (139 of 412) of patients, which was a significantly higher rate than that in the lower-GA-level group (24.6%, P\u2009=\u20090.002). According to multivariate linear regression analysis, a GA level\u2009&gt;\u200915.5% was independently associated with low responsiveness to clopidogrel after adjustment for age, sex and other conventional confounding factors. This interaction was not mediated by a history of diabetes mellitus. A GA level\u2009\u2264\u200915.5% was associated with a high positive value [75.4%, 95% CI 73.0\u201377.6%] for predicting a normal responsiveness to clopidogrel.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>GA could be a potential biomarker to predict the effects of clopidogrel antiplatelet therapy in ACS patients and might be a clinical biomarker to guide DAPT de-escalation.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12933-020-01146-w","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T08:02:58Z","timestamp":1602230578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["High glycated albumin is an independent predictor of low response to clopidogrel in ACS patients: a cross-sectional study"],"prefix":"10.1186","volume":"19","author":[{"given":"Xiliang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenchen","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9433-6140","authenticated-orcid":false,"given":"Yicong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,9]]},"reference":[{"key":"1146_CR1","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK, Smith SC Jr. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2016;68:1082\u2013115.","journal-title":"J Am Coll Cardiol"},{"key":"1146_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213\u201360.","journal-title":"Eur Heart J"},{"key":"1146_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO, Group ESCSD. 2018 ESC\/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40:87\u2013165.","journal-title":"Eur Heart J"},{"key":"1146_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.carrev.2018.01.009","volume":"19","author":"N Misumida","year":"2018","unstructured":"Misumida N, Aoi S, Kim SM, Ziada KM, Abdel-Latif A. Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: systematic review and meta-analysis. Cardiovasc Revasc Med. 2018;19:689\u201394.","journal-title":"Cardiovasc Revasc Med"},{"key":"1146_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1161\/CIRCULATIONAHA.120.046786","volume":"142","author":"EP Navarese","year":"2020","unstructured":"Navarese EP, Khan SU, Ko\u0142odziejczak M, Kubica J, Buccheri S, Cannon CP, Gurbel PA, De Servi S, Budaj A, Bartorelli A, Trabattoni D, Ohman EM, Wallentin L, Roe MT, James S. Comparative efficacy and safety of oral P2Y(12) inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials. Circulation. 2020;142:150\u201360.","journal-title":"Circulation"},{"key":"1146_CR6","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1002\/clc.23074","volume":"41","author":"XY Li","year":"2018","unstructured":"Li XY, Su GH, Wang GX, Hu HY, Fan CJ. Switching from ticagrelor to clopidogrel in patients with ST-segment elevation myocardial infarction undergoing successful percutaneous coronary intervention in real-world China: occurrences, reasons, and long-term clinical outcomes. Clin Cardiol. 2018;41:1446\u2013544.","journal-title":"Clin Cardiol"},{"key":"1146_CR7","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","volume":"49","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505\u201316.","journal-title":"J Am Coll Cardiol"},{"key":"1146_CR8","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","volume":"55","author":"W Hochholzer","year":"2010","unstructured":"Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, Buttner HJ, Neumann FJ. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol. 2010;55:2427\u201334.","journal-title":"J Am Coll Cardiol"},{"key":"1146_CR9","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","volume":"13","author":"DJ Angiolillo","year":"2020","unstructured":"Angiolillo DJ, Capodanno D, Danchin N, Simon T, Bergmeijer TO, Ten Berg JM, Sibbing D, Price MJ. Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score. JACC Cardiovasc Interv. 2020;13:606\u201317.","journal-title":"JACC Cardiovasc Interv"},{"key":"1146_CR10","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","volume":"382","author":"GW Stone","year":"2013","unstructured":"Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382:614\u201323.","journal-title":"Lancet"},{"key":"1146_CR11","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","volume":"62","author":"US Tantry","year":"2013","unstructured":"Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261\u201373.","journal-title":"J Am Coll Cardiol"},{"key":"1146_CR12","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","volume":"136","author":"DJ Angiolillo","year":"2017","unstructured":"Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, Sibbing D, So DYF, Trenk D, Alexopoulos D, Gurbel PA, Hochholzer W, De Luca L, Bonello L, Aradi D, Cuisset T, Tantry US, Wang TY, Valgimigli M, Waksman R, Mehran R, Montalescot G, Franchi F, Price MJ. International expert consensus on switching platelet P2Y(12) receptor-inhibiting therapies. Circulation. 2017;136:1955\u201375.","journal-title":"Circulation"},{"key":"1146_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa575","author":"JP Collet","year":"2020","unstructured":"Collet JP, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, J\u00fcni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa575.","journal-title":"Eur Heart J"},{"key":"1146_CR14","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.jacc.2007.05.049","volume":"50","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo DJ, Bernardo E, Sabate M, Jimenez-Quevedo P, Costa MA, Palazuelos J, Hernandez-Antolin R, Moreno R, Escaned J, Alfonso F, Banuelos C, Guzman LA, Bass TA, Macaya C, Fernandez-Ortiz A. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2007;50:1541\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"1146_CR15","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jacc.2014.06.1170","volume":"64","author":"DJ Angiolillo","year":"2014","unstructured":"Angiolillo DJ, Jakubowski JA, Ferreiro JL, Tello-Montoliu A, Rollini F, Franchi F, Ueno M, Darlington A, Desai B, Moser BA, Sugidachi A, Guzman LA, Bass TA. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol. 2014;64:1005\u2013144.","journal-title":"J Am Coll Cardiol"},{"key":"1146_CR16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11239-010-0547-4","volume":"32","author":"F Mangiacapra","year":"2011","unstructured":"Mangiacapra F, Peace AJ, Wijns W, Barbato E. Lack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel. J Thromb Thrombolysis. 2011;32:54\u20138.","journal-title":"J Thromb Thrombolysis"},{"key":"1146_CR17","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1160\/TH11-12-0876","volume":"108","author":"O Morel","year":"2012","unstructured":"Morel O, El Ghannudi S, Hess S, Reydel A, Crimizade U, Jesel L, Radulescu B, Wiesel ML, Gachet C, Ohlmann P. The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight. Thromb Haemost. 2012;108:338\u201348.","journal-title":"Thromb Haemost"},{"key":"1146_CR18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.amjcard.2015.10.037","volume":"117","author":"MM Schoos","year":"2016","unstructured":"Schoos MM, Dangas GD, Mehran R, Kirtane AJ, Yu J, Litherland C, Clemmensen P, Stuckey TD, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Brodie BR, Mazzaferri EL Jr, Maehara A, Stone GW. Impact of Hemoglobin A1c levels on residual platelet reactivity and outcomes after insertion of coronary drug-eluting stents (from the ADAPT-DES study). Am J Cardiol. 2016;117:192\u2013200.","journal-title":"Am J Cardiol"},{"key":"1146_CR19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S2213-8587(13)70199-2","volume":"2","author":"E Selvin","year":"2014","unstructured":"Selvin E, Rawlings AM, Grams M, Klein R, Sharrett AR, Steffes M, Coresh J. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 2014;2:279\u201388.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1146_CR20","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1161\/CIRCULATIONAHA.117.030190","volume":"137","author":"YD Tang","year":"2018","unstructured":"Tang YD, Wang W, Yang M, Zhang K, Chen J, Qiao S, Yan H, Wu Y, Huang X, Xu B, Gao R, Yang Y, Investigators C. Randomized comparisons of double-dose clopidogrel or adjunctive cilostazol versus standard dual antiplatelet in patients with high posttreatment platelet reactivity: results of the CREATIVE trial. Circulation. 2018;137:2231\u201345.","journal-title":"Circulation"},{"key":"1146_CR21","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jacc.2006.10.050","volume":"49","author":"KP Bliden","year":"2007","unstructured":"Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2007;49:657\u201366.","journal-title":"J Am Coll Cardiol"},{"key":"1146_CR22","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1016\/j.jacc.2005.07.041","volume":"46","author":"PA Gurbel","year":"2005","unstructured":"Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J Am Coll Cardiol. 2005;46:1820\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"1146_CR23","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ahj.2010.05.034","volume":"160","author":"PA Gurbel","year":"2010","unstructured":"Gurbel PA, Bliden KP, Navickas IA, Mahla E, Dichiara J, Suarez TA, Antonino MJ, Tantry US, Cohen E. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J. 2010;160:346\u201354.","journal-title":"Am Heart J"},{"key":"1146_CR24","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/MCA.0000000000000512","volume":"28","author":"Q Li","year":"2017","unstructured":"Li Q, Li M, Yu X, He J, Gao Y, Zhang X, Wu C, Luo Y, Zhang Y, Ren X. Impact of mean platelet aggregation degree on long-term clinical outcomes among patients undergoing a complex percutaneous coronary intervention. Coron Artery Dis. 2017;28:478\u201385.","journal-title":"Coron Artery Dis"},{"key":"1146_CR25","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1212\/WNL.0000000000001421","volume":"84","author":"J Li","year":"2015","unstructured":"Li J, Wang Y, Wang D, Lin J, Wang A, Zhao X, Liu L, Wang C, Wang Y. Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke. Neurology. 2015;84:1330\u20136.","journal-title":"Neurology"},{"key":"1146_CR26","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/jama.2011.290","volume":"305","author":"MJ Price","year":"2011","unstructured":"Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305:1097\u2013105.","journal-title":"JAMA"},{"key":"1146_CR27","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1007\/s00125-011-2310-6","volume":"54","author":"N Furusyo","year":"2011","unstructured":"Furusyo N, Koga T, Ai M, Otokozawa S, Kohzuma T, Ikezaki H, Schaefer EJ, Hayashi J. Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: results from the Kyushu and Okinawa Population Study (KOPS). Diabetologia. 2011;54:3028\u201336.","journal-title":"Diabetologia"},{"key":"1146_CR28","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.2337\/diabetes.54.8.2430","volume":"54","author":"DJ Angiolillo","year":"2005","unstructured":"Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Macaya C. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54:2430\u20135.","journal-title":"Diabetes"},{"issue":"784","key":"1146_CR29","first-page":"e781","volume":"158","author":"A Singla","year":"2009","unstructured":"Singla A, Antonino MJ, Bliden KP, Tantry US, Gurbel PA. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J. 2009;158(784):e781\u2013786.","journal-title":"Am Heart J"},{"key":"1146_CR30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.amjcard.2012.03.027","volume":"110","author":"W Kuliczkowski","year":"2012","unstructured":"Kuliczkowski W, Gasior M, Pres D, Kaczmarski J, Greif M, Laszewska A, Szewczyk M, Hawranek M, Tajstra M, Zeglen S, Polonski L, Serebruany V. Effect of glycemic control on response to antiplatelet therapy in patients with diabetes mellitus and ST-segment elevation myocardial infarction. Am J Cardiol. 2012;110:331\u20136.","journal-title":"Am J Cardiol"},{"key":"1146_CR31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12933-019-0952-8","volume":"18","author":"A Nusca","year":"2019","unstructured":"Nusca A, Tuccinardi D, Proscia C, Melfi R, Manfrini S, Nicolucci A, Ceriello A, Pozzilli P, Ussia GP, Grigioni F, Di Sciascio G. Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention. Cardiovasc Diabetol. 2019;18:147.","journal-title":"Cardiovasc Diabetol"},{"key":"1146_CR32","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.2337\/dc20-S002","volume":"43","author":"American Diabetes A","year":"2020","unstructured":"American Diabetes A. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S14\u2013S31.","journal-title":"Diabetes Care"},{"key":"1146_CR33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1590\/2359-3997000000272","volume":"61","author":"PAC Freitas","year":"2017","unstructured":"Freitas PAC, Ehlert LR, Camargo JL. Glycated albumin: a potential biomarker in diabetes. Arch Endocrinol Metab. 2017;61:296\u2013304.","journal-title":"Arch Endocrinol Metab"},{"key":"1146_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cca.2014.03.001","volume":"433","author":"M Koga","year":"2014","unstructured":"Koga M. Glycated albumin; clinical usefulness. Clin Chim Acta. 2014;433:96\u2013104.","journal-title":"Clin Chim Acta"},{"key":"1146_CR35","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(17)32279-1","volume":"390","author":"DJ Angiolillo","year":"2017","unstructured":"Angiolillo DJ. Dual antiplatelet therapy guided by platelet function testing. Lancet. 2017;390:1718\u201320.","journal-title":"Lancet"},{"key":"1146_CR36","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1517\/14656566.2012.666524","volume":"13","author":"M Karazniewicz-Lada","year":"2012","unstructured":"Karazniewicz-Lada M, Danielak D, Glowka F. Genetic and non-genetic factors affecting the response to clopidogrel therapy. Expert Opin Pharmacother. 2012;13:663\u201383.","journal-title":"Expert Opin Pharmacother"},{"key":"1146_CR37","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/09537100902795492","volume":"20","author":"DA Rubenstein","year":"2009","unstructured":"Rubenstein DA, Yin W. Glycated albumin modulates platelet susceptibility to flow induced activation and aggregation. Platelets. 2009;20:206\u201315.","journal-title":"Platelets"},{"key":"1146_CR38","doi-asserted-by":"publisher","first-page":"960","DOI":"10.2337\/db14-0879","volume":"64","author":"D Blache","year":"2015","unstructured":"Blache D, Bourdon E, Salloignon P, Lucchi G, Ducoroy P, Petit JM, Verges B, Lagrost L. Glycated albumin with loss of fatty acid binding capacity contributes to enhanced arachidonate oxygenation and platelet hyperactivity: relevance in patients with type 2 diabetes. Diabetes. 2015;64:960\u201372.","journal-title":"Diabetes"},{"key":"1146_CR39","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1080\/09537104.2016.1260703","volume":"28","author":"I Soaita","year":"2017","unstructured":"Soaita I, Yin W, Rubenstein DA. Glycated albumin modifies platelet adhesion and aggregation responses. Platelets. 2017;28:682\u201390.","journal-title":"Platelets"},{"key":"1146_CR40","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","volume":"124","author":"MJ Price","year":"2011","unstructured":"Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial. Circulation. 2011;124:1132\u20137.","journal-title":"Circulation"},{"key":"1146_CR41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1160\/TH10-07-0440","volume":"105","author":"J Jaitner","year":"2011","unstructured":"Jaitner J, Stegherr J, Morath T, Braun S, Bernlochner I, Schomig A, Kastrati A, Sibbing D. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. Thromb Haemost. 2011;105:107\u201312.","journal-title":"Thromb Haemost"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01146-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-020-01146-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01146-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T16:32:34Z","timestamp":1633883554000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-01146-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1146"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-01146-w","relation":{},"ISSN":["1475-2840"],"issn-type":[{"type":"electronic","value":"1475-2840"}],"subject":[],"published":{"date-parts":[[2020,10,9]]},"assertion":[{"value":"23 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board (IRB number: 2018075X) of Beijing Anzhen Hospital and was conducted according to the guidelines set forth in the Declaration of Helsinki. All patients provided written informed consent for participation in the present study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}